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Abstract
Introduction Recent clinical data suggest that early
administration of vasopressin analogues may be advantageous
compared to a last resort therapy. However, it is still unknown
whether vasopressin and terlipressin are equally effective for
hemodynamic support in septic shock. The aim of the present
prospective, randomized, controlled pilot trial study was,
therefore, to compare the impact of continuous infusions of
either vasopressin or terlipressin, when given as first-line therapy
in septic shock patients, on open-label norepinephrine
requirements.
Methods We enrolled septic shock patients (n = 45) with a
mean arterial pressure below 65 mmHg despite adequate
volume resuscitation. Patients were randomized to receive
continuous infusions of either terlipressin (1.3 μg·kg-1·h-1),
vasopressin (.03 U·min-1) or norepinephrine (15 μg·min-1; n = 15
per group). In all groups, open-label norepinephrine was added
to achieve a mean arterial pressure between 65 and 75 mmHg,
if necessary. Data from right heart and thermo-dye dilution
catheterization, gastric tonometry, as well as laboratory variables
of organ function were obtained at baseline, 12, 24, 36 and 48
hours after randomization. Differences within and between
groups were analyzed using a two-way ANOVA for repeated
measurements with group and time as factors. Time-
independent variables were compared with one-way ANOVA.
Results There were no differences among groups in terms of
systemic and regional hemodynamics. Compared with infusion
of .03 U of vasopressin or 15 μg·min-1 of norepinephrine, 1.3
μg·kg-1·h-1  of terlipressin allowed a marked reduction in
catecholamine requirements (0.8 ± 1.3 and 1.2 ± 1.4 vs. 0.2 ±
0.4  μg·kg-1·min-1  at 48 hours; each P  < 0.05) and was
associated with less rebound hypotension (P < 0.05). At the
end of the 48-hour intervention period, bilirubin concentrations
were higher in the vasopressin and norepinephrine groups as
compared with the terlipressin group (2.3 ± 2.8 and 2.8 ± 2.5
vs. 0.9 ± 0.3 mg·dL-1; each P  < 0.05). A time-dependent
decrease in platelet count was only observed in the terlipressin
group (P < 0.001 48 hours vs. BL).
Conclusions The present study provides evidence that
continuous infusion of low-dose terlipressin – when given as
first-line vasopressor agent in septic shock – is effective in
reversing sepsis-induced arterial hypotension and in reducing
norepinephrine requirements.
Trial registration ClinicalTrial.gov NCT00481572.
ANOVA: analysis of variance; AVP: arginine vasopressin; BILD: direct bilirubin; BILT: total bilirubin; CBI: blood clearance of indocyanine green related 
to body surface area; CI: cardiac index; DO2I: systemic oxygen delivery index; FiO2: fraction of inspired oxygen; HR: heart rate; ICU: intensive care 
unit; IL: interleukin; LVSWI: left ventricular stroke work index; MAP: mean arterial pressure; MPAP: mean pulmonary arterial pressure; NE: norepine-
phrine; O2-ER: oxygen extraction rate; PaO2: partial pressure of arterial oxygen; PAOP: pulmonary arterial occlusion pressure; PDR: plasma disap-
pearance rate of indocyanine green; PVRI: pulmonary vascular resistance index; RAP: right atrial pressure; RVSWI: right ventricular stroke work index; 
SAPS II: Simplified Acute Physiology Score II; SD: standard deviation; SvO2: mixed-venous oxygen saturation; SVRI: systemic vascular resistance 
index; TNF: tumor necrosis factor; TP: terlipressin; VASST: Vasopressin and Septic Shock Trial; VO2I: systemic oxygen consumption index.Critical Care    Vol 13 No 4    Morelli et al.
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Introduction
In the past few years, it has become evident that the efficacy
of hemodynamic optimization by fluids and vasopressor
agents critically depends on the urgency of therapy [1-4]. The
recent Vasopressin and Septic Shock Trial (VASST) [5]
revealed that survival was only improved in the subgroup of
patients receiving vasopressin (AVP) in the less severe state
of disease, as indicated by low doses of norepinephrine (NE)
infusion (i.e. ≤15 μg/min) prior to randomization. In some Euro-
pean countries, however, AVP is not available, and thus ter-
lipressin (TP), a synthetic, long-acting vasopressin analogue,
is commonly considered as last resort therapy in the late
phase of septic shock, when high dosages of catecholamines
fail to counteract sepsis-related arterial hypotension [6-9]. Due
to its long effective half-life of four to six hours, TP is commonly
administered as high-dose bolus infusion (about 1 mg every
four to six hours). The potential problem, however, is that TP
bolus infusion may contribute to excessive vasoconstriction
and a reflectory decrease in cardiac output with a proportional
depression in oxygen delivery [10]. This may be especially
problematic in a condition of increased oxygen demand, such
as early sepsis [1,3]. Notably, preliminary experimental and
clinical reports have shown that TP may also be administered
as low-dose continuous infusion, thereby mitigating, or even
preventing such adverse events [10-14]. The optimal time of
therapy, however, remains to be determined.
Preliminary results from a comparative experimental study of
AVP versus TP in ovine septic shock suggested that continu-
ous infusion of TP may improve survival and increase
mesenteric perfusion as compared with AVP [15]. In addition,
it has been reported that a highly selective V1 agonist (FE
202158) markedly reduced vascular leakage and mortality in
experimental sepsis as compared with AVP [16,17]. Neverthe-
less, a direct comparison between a continuous infusion of a
relatively selective V1 agonist, such as TP, and AVP on cate-
cholamine requirements in human septic shock has not yet
been performed. We hypothesized that the relatively selective
V1 receptor agonist TP is likewise advantageous when com-
pared with AVP in human septic shock.
Therefore, we conducted a randomized controlled clinical pilot
study to compare the effects of first-line institution of continu-
ous, fixed doses of TP and AVP infusion on open-label NE
requirements in patients with septic shock. In addition, we
aimed to investigate the effects of both vasopressor agents on
systemic and regional hemodynamics as well as organ func-
tion.
Materials and methods
Patients
After approval by the Local Institutional Ethics Committee, the
study was performed in an 18-bed multidisciplinary intensive
care unit (ICU) of the Department of Anesthesiology and Inten-
sive Care of the University of Rome 'La Sapienza'. Due to the
protocol design, informed consent was obtained from the
patients' next of kin at the time of ICU admission. Enrolment of
patients started in January 2007 and ended in January 2008.
We enrolled patients who fulfilled the criteria of septic shock
[3] presenting with a mean arterial pressure (MAP) below 65
mmHg despite appropriate volume resuscitation (pulmonary
arterial occlusion pressure (PAOP) = 12 to 18 mmHg and
central venous pressure = 8 to 12 mmHg) [3] during the ICU
stay.
Exclusion criteria were age less than 18 years, catecholamine
therapy prior to randomization, pronounced cardiac dysfunc-
tion (i.e. cardiac index ≤2.2 L/min/m in the presence of PAOP
> 18 mmHg), chronic renal failure, severe liver dysfunction
(Child-Turcotte-Pugh grade C), significant valvular heart dis-
ease, present coronary artery disease, pregnancy, and present
or suspected acute mesenteric ischemia or vasospastic dia-
thesis (e.g. Raynaud's syndrome or related diseases).
All patients were sedated with sufentanil and midazolam and
received mechanical ventilation using a volume-controlled
mode.
Measurements
Systemic hemodynamic monitoring of the patients included a
pulmonary artery catheter (7.5-F, Edwards Lifesciences, Irvine,
CA, USA) and a radial artery catheter. MAP, right atrial pres-
sure (RAP), mean pulmonary arterial pressure (MPAP), and
PAOP were measured at end-expiration. Heart rate (HR) was
analyzed from a continuous recording of electrocardiogram
with ST segments monitored. Cardiac index (CI) was meas-
ured using the continuous thermodilution technique (Vigilance
II®, Edwards Lifesciences, Irvine, CA, USA). Arterial and
mixed-venous blood samples were taken to determine oxygen
tensions and saturations, as well as carbon dioxide tensions,
standard bicarbonate and base excess. Mixed-venous oxygen
saturation (SvO2) was measured discontinuously by intermit-
tent mixed-venous blood gas analyses. Systemic vascular
resistance index (SVRI), pulmonary vascular resistance index
(PVRI), left and right ventricular stroke work indices (LVSWI,
RVSWI), systemic oxygen delivery index (DO2I), oxygen con-
sumption index (VO2I), and oxygen extraction ratio (O2-ER)
were calculated using standard formulae.
Regional hemodynamic monitoring was performed using a 4-F
oximetry thermo-dye dilution catheter (PV2024L, Pulsion Med-
ical System AG, Munich, Germany) inserted into the femoral
artery for the measurement of plasma disappearance rate
(PDR) and blood clearance of indocyanine green related to
body surface area (CBI). PDR and CBI were determined with
the Cold Z-021 system (Pulsion Medical System AG, Munich,
Germany) using an established protocol [18,19]. In addition,
an air-tonometer (Tonocap, Datex-Ohmeda, Helsinki, Finland)
was inserted via the naso-gastric route for measurement of
gastric mucosal carbon dioxide partial pressure and calcula-Available online http://ccforum.com/content/13/4/R130
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tion of the gradient between gastric mucosal and partial pres-
sure of arterial carbon dioxide [20,21].
Arterial blood samples were drawn and analyzed for pH, arte-
rial lactate, aspartate aminotransferase, alanine aminotrans-
ferase, total bilirubin (BILT), direct bilirubin (BILD), amylase,
lipase, international normalized ratio, activated partial thrombo-
plastin time ratio, cardiac troponin I, TNF-α, IL-1β, and IL-6.
Urine samples were collected to assess urinary output and
creatinine clearance.
Study design
Patients were randomized to one of three study groups using
a computer-based procedure. Patients allocated to the TP
group received a continuous TP infusion of 1.3 μg/kg/hour
and patients in the AVP group were treated with a continuous
infusion of AVP at 0.03 U/min. The control group received a
fixed dose of NE (15 μg/min). In all three groups, open-label
NE was additionally infused, if the goal MAP of 70 ± 5 mmHg
was not achieved with study drug infusion alone (Figure 1).
Fluid challenge was performed to maintain central venous
pressure at 8 to 12 mmHg and PAOP between 12 and 18
mmHg during the 48-hour intervention period [3]. Packed red
blood cells were transfused when hemogloblin concentrations
decreased below 8 g/dL. If SvO2 was less than 65% despite
appropriate arterial oxygenation (arterial oxygen saturation
≥95%) and hemoglobin concentrations wer 8 g/dL or above,
dobutamine was administered in doses up to 20 μg/kg/min to
achieve SvO2 values of 65% or more, if possible [3]. During
the 48-hour study period, all patients received intravenous
hydrocortisone (200 mg/day) as a continuous infusion.
Systemic, pulmonary, and regional hemodynamic measure-
ments, laboratory variables, blood gases as well as NE require-
ments, were determined at baseline, 12, 24, 36 and 48 hours
after randomization. Plasma cytokine concentrations were
measured at baseline and after 48 hours.
In patients surviving the 48-hour intervention period, study
drug infusion was terminated, and open-label NE was titrated
to maintain MAP at 70 ± 5 mmHg. To assess the incidence of
arterial rebound hypotension, NE infusion rates were again
evaluated at 54 and 60 hours after randomization (i.e. 6 and
12 hours after termination of study drug infusion). None of the
patients received further TP or AVP infusions.
Statistical analysis
The primary endpoint of the present study was the reduction
of average open-label NE requirements in patients treated with
TP as compared with the AVP or NE group. To detect a 30%
difference in NE infusion rates between groups, with an
expected standard deviation (SD) of 25% and a test power of
the analysis of variance (ANOVA) of 80%, a sample size of 15
individuals per group was required. Data are expressed as
means ± SD, if not otherwise specified. Sigma Stat 3.10 soft-
ware (SPSS, Chicago, IL, USA) was used for statistical analy-
sis. After confirming normal distribution of all variables
(Kolmogorov-Smirnov test), differences within and among
groups were analyzed using a two-way ANOVA for repeated
measurements with group and time as factors. Time-independ-
ent variables were compared with one-way ANOVA. In case of
significant group differences over time, appropriate post hoc
comparisons (Student-Newman-Keuls) were performed. Cate-
gorical data were compared using the chi-squared test. For all
Figure 1
Study design Study design. AVP = arginine vasopressin; MAP = mean arterial pressure; NE = norepinephrine; TP = terlipressin.Critical Care    Vol 13 No 4    Morelli et al.
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tests, an α-error probability of P < 0.05 was considered as sta-
tistically significant.
Results
Patients
Of the 119 screened septic shock patients who met the inclu-
sion criteria of the study, 74 had to be excluded due to prior
catecholamine therapy (n = 62), inappropriately low cardiac
output (n = 7), chronic renal failure (n = 4), and severe liver
dysfunction (n = 1). Finally, 45 consecutive patients were
enrolled in the study and equally randomized to one of the
three study groups (n = 15 per group; Figure 1). None of the
enrolled patients died during the study period.
Demographic data
Baseline characteristics including age, gender, body weight,
origin of septic shock, and simplified acute physiology score II
(SAPS II) are presented in Table 1. There were no significant
differences in baseline characteristics between groups.
Norepinephrine and dobutamine requirements
Open-label NE infusion rates increased over time in the AVP
and NE groups (each P < 0.001 at 48 hours vs. baseline; Fig-
ure 2). Likewise, NE requirements increased during the first
two hours of the study period in the TP group (P < 0.001).
From 24 hours to the end of the intervention period, however,
open-label NE infusion rates were significantly lower in the TP
group as compared with the AVP and NE groups (P = 0.02 vs.
AVP and P  < 0.001 vs. NE at 48 hours). In addition, NE
requirements were significantly higher 12 hours after discon-
tinuation of the study drugs in the NE and AVP group as com-
pared with the TP group (each P = 0.018 vs. AVP and NE at
60 hours). At six hours, dobutamine requirements were higher
in TP-treated patients as compared with the other two groups.
However, thereafter dobutamine doses were similar between
groups during the first 12 hours of initial hemodynamic resus-
citation (Figure 3). Activated protein C was administered in
four patients in NE group and in five patients in both TP and
AVP groups.
Systemic hemodynamic variables
Systemic hemodynamic variables are summarized in Table 2.
HR was significantly lower in the TP group as compared with
the NE group over the whole interventional period (P = 0.047).
There was no significant overall group difference in the other
variables of systemic hemodynamics.
New-onset tachyarrhythmias
The incidence of new-onset tachyarrhythmias (i.e atrial fibrilla-
tion) was 0 of 15 in the TP group, 1 of 15 in the AVP group
and 4 of 15 in patients allocated to the control group (not sig-
nificant; P = 0.054; chi-squared test).
Acid-base homeostasis, oxygen transport variables
There were no significant overall differences between groups
in any variable of acid-base homeostasis or oxygen transport,
except for a lower pH and base excess as well as a higher arte-
rial lactate concentration in the NE as compared with the TP
group at 48 hours (Table 3).
Regional hemodynamics
There were no significant overall differences between groups
in any variable of regional hemodynamics. Nevertheless, a
time-dependent decrease in PDR and CBI was observed in
the AVP and NE groups (both P < 0.05 at 48 hours vs. base-
line; Table 4).
Table 1
Baseline characteristics, length of stay and outcome of the study patients
TP (n = 15) AVP (n = 15) NE (n = 15) P value
Age, years 67 (60; 71) 66 (60; 74) 64 (59; 72) 0.889
Gender, male 73% 67% 80% 0.717
Body weight, kg 85 (79; 100) 85 (71; 98) 85 (78; 90) 0.612
SAPS II 62 (57; 72) 60 (49; 66) 58 (52; 68) 0.664
Cause of septic shock Necrotizing fasciitis (n = 1) Endocarditis (n = 1) Pancreatitis (n = 4) 0.438
Pancreatitis (n = 3) Necrotizing fasciitis (n = 2) Peritonitis (n = 6)
Peritonitis (n = 5) Peritonitis (n = 6) Pneumonia (n = 5)
Pneumonia (n = 6) Pneumonia (n = 6)
ICU mortality 7/15 8/15 10/15 0.533
ICU length of stay 14 (9; 25) 17 (5; 27) 17(7; 23) 0.878
Data are given as median (25%; 75% range).
AVP = arginine vasopressin; ICU = intensive care unit; NE = norepinephrine; TP = terlipressin; SAPS II = simplified acute physiology score II.Available online http://ccforum.com/content/13/4/R130
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Variables of organ function and injury
Variables of organ function and coagulation were similar
between groups (Table 5), except for BILT and BILD, which
were significantly higher in the AVP and NE group as com-
pared with patients treated with TP at the end of the 48-hour
intervention period (BILT: TP vs. NE, P = 0.001; TP vs. AVP,
P = 0.009; BILD: TP vs. NE, P = 0.002; TP vs. AVP, P =
0.013).
Creatinine plasma concentrations increased with time only in
the NE group (P < 0.001 at 48 hours vs. baseline). The relative
increase in creatinine concentrations over the 48-hour inter-
vention period was significantly higher in the NE group as
compared with the TP and AVP group (each P  < 0.001).
Whereas 4 of 15 (26.7%) and 5 of 15 (33.3%) patients
required renal replacement therapy at the end of the study
period in the TP and AVP group, respectively, 8 of 15 patients
(53.3%) required renal replacement therapy at the end of the
study period in the NE group (n.s.; P = 0.293; chi-squared
test). There were no differences in coagulation variables
except for a time-dependent decrease in platelet count in the
TP group (P < 0.001 at 48 hours vs. baseline).
Markers of systemic inflammation
IL-6 concentrations significantly decreased in the AVP group
(P = 0.044 at 48 hours vs. baseline), and there was a strong
tendency towards a decrease in the TP group (P = 0.052 at
48 hours vs. baseline). However, there were no significant dif-
ferences in TNF-α or IL-1β concentrations among groups
(Table 6).
Length of ICU stay and outcome
Length of ICU stay and ICU mortality were similar between
groups (Table 1).
Discussion
The major findings of the present study are that continuous,
low-dose TP infusion at the investigated dose was effective in
reversing sepsis-induced arterial hypotension and in reducing
NE requirements.
In the current clinical trial, TP, AVP and NE – when adminis-
tered as first-line vasopressor agents – were effective in
increasing MAP to goal values of 70 ± 5 mmHg when com-
bined with open-label NE. The vasoconstrictive effects of AVP
and TP mainly depend on V1 receptor stimulation. Neverthe-
less, AVP may also exert vasodilatory effects in a dose-
dependent manner, possibly mediated by nitric oxide liberation
secondary to stimulation of V2 receptors [22]. In this context,
Barrett and colleagues [23] recently reported that the selec-
tive V1 agonist F-180 is a more effective vasoconstrictor agent
as compared with AVP. The latter observation is in accord-
ance with the finding of the present study that TP, a relatively
selective V1 agonist as compared with AVP (V1:V2 ratio of
2.2:1 vs. 1:1) [22], enabled a marked reduction in open-label
NE requirements. As expected, due to its effective half-life of
four to six hours, we noticed a longer duration of the TP effects
(i.e. lack of rebound hypotension) [22].
The somewhat surprising observation of the present study that
AVP only tended to but did not significantly reduce NE require-
ments is in contrast with the results of VASST (which used an
identical vasopressin dose), in which AVP administration
allowed a reduction in NE requirements [5]. However, there
Figure 2
Norepinephrine requirements Norepinephrine requirements. AVP = arginine vasopressin; NE = nore-
pinephrine; TP = terlipressin. ‡ P < 0.05 vs. AVP (significant group 
effect); § P < 0.05 vs. NE (significant group effect).
Figure 3
Dobutamine requirements Dobutamine requirements. AVP = arginine vasopressin; MAP = mean 
arterial pressure; NE = norepinephrine; TP = terlipressin. ‡P < 0.05 vs. 
AVP (significant group effect); § P < 0.05 vs. NE (significant group 
effect).Critical Care    Vol 13 No 4    Morelli et al.
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Table 2
Hemodynamic variables
Baseline 12 hours 24 hours 36 hours 48 hours
HR
(bpm)
TP 95 ± 16 85 ± 19* 83 ± 21* 71 ± 14*‡§ 71 ± 16*‡§
AVP 100 ± 22 98 ± 24 97 ± 27 92 ± 24† 93 ± 25†
NE 97 ± 21 92 ± 26 99 ± 29 95 ± 24† 96 ± 21†
CI
(L/min/m)
TP 4.0 ± 1.0 3.9 ± 1.0 3.7 ± 0.8 3.4 ± 0.6 3.5 ± 0.6
AVP 4.0 ± 1.1 4.2 ± 1.4 4.3 ± 1.1 3.9 ± 1.1 4.2 ± 1.9
NE 4.0 ± 1.0 3.9 ± 1.0 4.1 ± 1.1 3.9 ± 1.2 3.9 ± 1.5
SVI
(mL/beats/m)
TP 46 ± 13 46 ± 13 47 ± 12 48 ± 10 50 ± 10
AVP 41 ± 12 43 ± 12 46 ± 10 44 ± 12 47 ± 18
NE 43 ± 13 44 ± 14 44 ± 15 43 ± 16 42 ± 15
MAP
(mmHg)
TP 53 ± 6 70 ± 3* 71 ± 3* 72 ± 3* 71 ± 4*
AVP 53 ± 4 70 ± 3* 70 ± 3* 71 ± 3* 71 ± 3*
NE 54 ± 3 70 ± 4* 71 ± 2* 7 0 ± 3* 71 ± 3*
MPAP
(mmHg)
TP 25 ± 4 27 ± 4* 27 ± 4* 27 ± 5* 28 ± 5*
AVP 24 ± 4 28 ± 5* 28 ± 5* 28 ± 5* 29 ± 4*
NE 24 ± 7 28 ± 7* 29 ± 7* 29 ± 5* 30 ± 7*
PAOP
(mmHg)
TP 15 ± 2 17 ± 2 17 ± 2 17 ± 2 17 ± 2
AVP 15 ± 2 17 ± 2* 17 ± 4* 17 ± 3* 17 ± 2*
NE 15 ± 2 15 ± 2 16 ± 2 16 ± 2 16 ± 3
RAP
(mmHg)
TP 11 ± 3 12 ± 3 14 ± 3* 13 ± 3 13 ± 3
AVP 12 ± 3 15 ± 3* 14 ± 3* 15 ± 3* 15 ± 4*
NE 12 ± 3 13 ± 3 14 ± 3 14 ± 4 14 ± 4
SVRI
(dyne·s/cm/m)Available online http://ccforum.com/content/13/4/R130
Page 7 of 14
(page number not for citation purposes)
are several reasons that might explain this discrepancy. First,
the considerably higher sample size of VASST as compared
with the present study makes it more likely to detect significant
differences. Moreover, in VASST [5], MAP at baseline was 72
to 73 mmHg, whereas it was considerably lower in the present
study. Second, the mean time elapsed from meeting the crite-
ria for study entry to infusion of AVP was 12 hours in VASST
[5]. By contrast, in our study, a different hemodynamic condi-
tion at baseline (i.e. arterial hypotension), as well as the admin-
istration of AVP as a first-line therapy could have played a
pivotal role in this regard [4]. In addition, the lack of reduction
in NE requirements may potentially be explained by the low
dose infused in the present study (0.03 U/min). Although pre-
vious studies suggest that AVP infusion in septic shock should
not exceed 0.04 U/min because of the potential risk of adverse
effects [3,24], Luckner and colleagues [25] recently reported
that 0.067 U/min is more effective in hemodynamic support
and catecholamine reduction than 0.033 U/min. Finally, it has
to be underlined that this specific dose has not yet been inves-
tigated as first-line therapy in the treatment of human septic
shock. Therefore, it is possible that in the present study, TP
was more effective than AVP because the TP dose was rela-
tively higher as compared with the vasopressin dose.
In harmony with previous experimental and clinical studies [11-
14], we did not notice a decrease in CI, DO2I and SvO2 follow-
ing low-dose AVP or TP infusion in fluid resuscitated septic
shock patients. In this regard, it is important to underline that
TP 886 ± 291 1271 ± 334* 1287 ± 304* 1376 ± 241* 1348 ± 275*
AVP 861 ± 246 1157 ± 407* 1091 ± 325* 1235 ± 334* 1254 ± 531*
NE 874 ± 220 1237 ± 320* 1208 ± 348* 1266 ± 386* 1319 ± 471*
PVRI
(dyne·s/cm/m)
TP 196 ± 61 227 ± 99 219 ± 89 256 ± 108 260 ± 117
AVP 200 ± 83 243 ± 108 230 ± 128 254 ± 148 264 ± 134
NE 192 ± 115 266 ± 106* 275 ± 122* 298 ± 133* 313 ± 202*
RVSWI
(g/m/beat)
TP 8 ± 4 9 ± 4 8 ± 5 9 ± 4 10 ± 4
AVP 7 ± 3 8 ± 3 9 ± 3* 8 ± 3 9 ± 4*
NE 7 ± 3 9 ± 4* 9 ± 3* 8 ± 3* 9 ± 4*
LVSWI
(g/m/beat)
TP 22 ± 7 33 ± 9* 35 ± 10* 37 ± 8* 37 ± 9*
AVP 21 ± 7 31 ± 8* 32 ± 6* 33 ± 9* 34 ± 14*
NE 22 ± 7 33 ± 11* 33 ± 12* 32 ± 13* 31 ± 11*
Fluids
(mL/24 h)
TP 4833 ± 783 4353 ± 853
AVP 4860 ± 686 4513 ± 781
NE 4707 ± 860 4807 ± 853
AVP = arginine vasopressin; CI = cardiac index; HR = heart rate; LVSWI = left ventricular stroke work index; MAP = mean arterial pressure; 
MPAP = mean pulmonary arterial pressure; NE = norepinephrine; PAOP = pulmonary artery occlusion pressure; PVRI = pulmonary vascular 
resistance index; RAP = right atrial pressure; RVSWI = right ventricular stroke work index; SVI = stroke volume index; SVRI = systemic vascular 
resistance index; TP = terlipressin.
*P < 0.05 vs. baseline (significant time effect); † P < 0.05 vs. TP (significant group effect); ‡P < 0.05 vs. AVP (significant group effect); §P < 0.05 
vs. NE (significant group effect).
Table 2 (Continued)
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Table 3
Oxygenation profile, acid-base variables and hemoglobin concentrations
Baseline 12 hours 24 hours 36 hours 48 hours
PH
(-log10 c(H+))
TP 7.31 ± 0.1 7.32 ± 0.1 7.32 ± 0.1 7.34 ± 0.08 7.37 ± 0.08*
AVP 7.36 ± 0.09 7.35 ± 0.11 7.32 ± 0.12 7.34 ± 0.12 7.32 ± 0.11
NE 7.34 ± 0.1 7.34 ± 0.08 7.32 ± 0.08 7.31 ± 0.09 7.28 ± 0.12*†
PaO2/FiO2
TP 176 ± 105 179 ± 82 189 ± 86 216 ± 95 220 ± 78
AVP 219 ± 118 231 ± 117 222 ± 129 211 ± 132 225 ± 133
NE 200 ± 97 216 ± 113 213 ± 101 194 ± 73 185 ± 85
PaO2
(mmHg)
TP 113 ± 44 127 ± 45 141 ± 47 164 ± 66 175 ± 64
AVP 123 ± 36 140 ± 48 130 ± 49 127 ± 59 139 ± 58
NE 120 ± 46 124 ± 44 125 ± 31 123 ± 34 114 ± 49
pvO2
(mmHg)
TP 36 ± 6 36 ± 6 36 ± 5 35 ± 5 36 ± 5
AVP 35 ± 6 38 ± 6 38 ± 5 38 ± 6 38 ± 6
NE 36 ± 7 38 ± 6 38 ± 6 39 ± 7 38 ± 6
SaO2
(%)
TP 96 ± 4 97 ± 3 98 ± 2 99 ± 2 99 ± 2
AVP 97 ± 3 98 ± 3 98 ± 2 96 ± 4 98 ± 2
NE 97 ± 2 96 ± 7 98 ± 1 98 ± 2 96 ± 7
SvO2
(%)
TP 60 ± 7 59 ± 11 60 ± 9 60 ± 8 63 ± 8
AVP 61 ± 12 65 ± 11 64 ± 7 63 ± 13 64 ± 12
NE 62 ± 10 66 ± 10 66 ± 9 66 ± 9 62 ± 12
DO2I
(mL/min/m)
TP 473 ± 105 468 ± 117 433 ± 92 393 ± 73 402 ± 70
AVP 464 ± 137 519 ± 189 550 ± 165 484 ± 123 520 ± 242
NE 460 ± 131 471 ± 157 482 ± 136 462 ± 136 467 ± 162
VO2I
(mL/min/m)
TP 184 ± 58 184 ± 49 171 ± 32 160 ± 43 152 ± 38
AVP 173 ± 51 173 ± 59 193 ± 65 168 ± 52 173 ± 51
NE 163 ± 41 147 ± 35 160 ± 57 153 ± 51 164 ± 67
O2-ER
(%)
TP 38 ± 6 40 ± 9 40 ± 8 41 ± 8 38 ± 8
AVP 39 ± 12 35 ± 9 35 ± 6 36 ± 11 37 ± 10Available online http://ccforum.com/content/13/4/R130
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dobutamine doses administered to achieve SvO2 values of
65% or moreduring the initial phase of hemodynamic resusci-
tation were similar between groups. In addition, neither AVP
nor TP negatively affected pulmonary hemodynamics and
function, as suggested by constant PVRI values and partial
pressure of arterial oxygen (PaO2)/fraction of inspired oxygen
(FiO2) ratio. These findings confirm the theory that continuous
TP infusion may be favourable over TP bolus infusion, because
the latter approach has been reported to excessively increase
SVRI and PVRI, as well as to decrease HR and CI [11].
Previous studies investigating low-dose AVP or TP in patients
with septic shock following adequate fluid resuscitation
reported few or no unwanted side effects within the splanch-
nic circulation [7,26-29]. In agreement with these previous
studies, we did not find significant overall differences among
groups in terms of arterial lactate concentrations or acid-base
homeostasis, as well as surrogate markers of splanchnic per-
fusion. The absence of detrimental hepatosplanchnic hemody-
namic effects of TP and AVP during the observation period is
further confirmed by the lack of significant overall differences
among groups in terms of liver and pancreatic enzymes. Nev-
ertheless, at the end of the study period, both BILT and BILD
were significantly higher in both the AVP and NE group as
compared with patients treated with TP. The increase in BILT
in the AVP group noticed in the present study is in agreement
with previous studies [25,27,30] reporting similar findings
after AVP administration. In contrast, we did not find any differ-
ences in BILT 48 hours after TP administration. It has been
postulated that AVP might contribute to an increase in BILT
concentrations by a reduction of biliary output and bile flow
after an initial transient increase [31]. In addition, it has been
shown that AVP may modulate hepatocyte tight junctional per-
meability and thus produce cholestasis [32]. Although specu-
lative, it is possible that these effects are less pronounced
when TP is administered, probably due to its higher V1 selec-
tivity. Nevertheless, the implication of this finding for the
course of the disease remains uncertain and should be clari-
fied in future studies.
Although AVP may contribute to antidiuresis in a dose-
dependent manner [33], recent studies revealed that in the
presence of septic shock, vasopressin analogues may
increase diuresis and improve renal function [7-
NE 37 ± 10 32 ± 6 34 ± 9 34 ± 9 36 ± 10
PaCO2
(mmHg)
TP 45 ± 6 42 ± 6 41 ± 9 40 ± 8 38 ± 6
AVP 43 ± 9 40 ± 5 42 ± 4 41 ± 6 41 ± 6
NE 44 ± 9 43 ± 9 44 ± 8 44 ± 8 43 ± 9
ABE
(mmol/L)
TP -2.9 ± 5.1 -4.6 ± 4.2 -4.9 ± 4.6 -4.0 ± 4.2 -3.1 ± 4.2
AVP -1.8 ± 6.5 -2.8 ± 7.0 -3.7 ± 6.7 -1.6 ± 7.8 -4.1 ± 6.5
NE -2.5 ± 4.5 -2.5 ± 4.3 -3.5 ± 4.3 -4.2 ± 3.9 -6.2 ± 5.4*
Arterial lactate
(mmol/L)
TP 3.1 ± 1.8 2.9 ± 1.9 2.9 ± 2.0 3.4 ± 2.4 3.6 ± 3.0
AVP 3.0 ± 2.4 3.2 ± 2.3 3.4 ± 2.3 3.2 ± 2.3 3.4 ± 3.3
NE 3.1 ± 2.2 3.3 ± 2.8 3.4 ± 2.8 3.6 ± 2.4 4.3 ± 3.4*
Hemoglobin
(g/dL)
TP 8.6 ± 0.9 8.7 ± 0.7 8.4 ± 1.2 8.2 ± 0.6‡ 8.1 ± 0.6
AVP 8.3 ± 0.9 8.7 ± 1.1 9 ± 1.1* 9 ± 1*† 8.8 ± 0.9
NE 8.3 ± 0.8 8.7 ± 0.9 8.4 ± 0.5 8.5 ± 0.8 8.9 ± 1
ABE = arterial base excess; AVP = arginine vasopressin; DO2I = oxygen delivery index; NE = norepinephrine; O2-ER = oxygen extraction rate; 
PaCO2 = partial pressure of arterial carbon dioxide; PaO2/FiO2 = ratio of oxygen tension over inspired oxygen concentration; PaO2 = partial 
pressure of arterial oxygen; pH = arterial pH; pvO2 = mixed venous oxygen tension; SaO2 = arterial oxygen saturation; SvO2 = mixed venous 
oxygen saturation; VO2I = oxygen consumption index; TP = terlipressin.
* P < 0.05 vs. baseline (significant time effect); † P < 0.05 vs. TP (significant group effect); ‡ P < 0.05 vs. AVP (significant group effect); § P < 0.05 
vs. NE (significant group effect).
Table 3 (Continued)
Oxygenation profile, acid-base variables and hemoglobin concentrationsCritical Care    Vol 13 No 4    Morelli et al.
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9,24,26,28,29]. Different pharmacological effects on the affer-
ent and efferent arterioles [34], as well as the pathophysiolog-
ical features in vasopressin receptor physiology in sepsis [35]
may account for these observations [7-9,24,26,28,29]. More-
over, the AVP-associated increase in systemic blood pressure
may contribute to an increase in urine output [36]. Notably, a
post hoc analysis of the VASST data [37] demonstrated a
reduced rate of progression to acute renal failure in patients at
risk for acute renal failure ('R', according to the RIFLE criteria
[38]) treated with AVP. In harmony with the latter observation
[37], neither AVP nor TP negatively affected renal function in
the present study.
AVP has been reported to activate platelets via V1 receptors,
leading to an increase in CD62 expression [39,40] and a
decrease in platelet count in patients with normal platelets, but
not in patients with low platelets [39]. In this context, it is
another interesting finding of the present study that TP, as
compared with AVP and NE, significantly decreased platelet
count. However, in accordance with a previous study [40], nei-
ther AVP nor NE negatively affected the coagulation system.
The present study has some limitations that we would like to
acknowledge. First, because there are no equivalent doses or
data comparing different doses of AVP and TP, we decided to
evaluate the efficacy of fixed doses of the study drugs in reach-
ing the threshold MAP and to investigate their effects on open-
label NE requirements. We therefore chose the AVP dose
investigated in VASST (i.e. 0.03 U/min of AVP and 15 μg/min
of NE) [5] and a low TP dose previously reported to be safe
and effective in a case series [13]. In this regard, it needs to
be considered that AVP was administered at a fixed dose of
Table 4
Regional hemodynamics
Baseline 12 hours 24 hours 36 hours 48 hours
CBI
(mL/min/m)
TP 353 ± 226 387 ± 202 367 ± 179 299 ± 139 351 ± 129
AVP 397 ± 171 409 ± 209 367 ± 222 308 ± 185* 305 ± 201*
NE 327 ± 135 358 ± 173 312 ± 145 271 ± 136 252 ± 206
PDR
(%)
TP 13 ± 6 14 ± 5 13 ± 4 12 ± 5 13 ± 4
AVP 15 ± 5 15 ± 6 13 ± 7 12 ± 7* 11 ± 6*
NE 14 ± 5 13 ± 5 12 ± 6 11 ± 6* 10 ± 7*
Pg-aCO2
(mmHg)
TP 23 ± 11 24 ± 8 22 ± 6 20 ± 6 20 ± 7
AVP 25 ± 7 28 ± 8 27 ± 9 28 ± 12 28 ± 10
NE 24 ± 11 28 ± 10 28 ± 8 26 ± 8 31 ± 12
Urinary output
(mL/h)
TP 34.6 ± 31.3 69.3 ± 70.4 49.2 ± 49.5 48.5 ± 41.4 46.6 ± 33.3
AVP 42.3 ± 46.9 42 ± 39 42 ± 41.6 40.7 ± 45.7 43.3 ± 58.7
NE 38.6 ± 34.3 55.4 ± 74.1 66 ± 77 58.6 ± 56.1 58.6 ± 63.8
AVP = arginine vasopressin; CBI = blood clearance of indocyanine green; NE = norepinephrine; PDR = plasma disappearance rate of 
indocyanine green; Pg-aCO2 = gastric-mucosal arterial carbon dioxide partial pressure difference; TP = terlipressin.
* P < 0.05 vs. baseline (significant time effect); † P < 0.05 vs. TP (significant group effect); ‡ P < 0.05 vs. AVP (significant group effect); § P < 0.05 
vs. NE (significant group effect).Available online http://ccforum.com/content/13/4/R130
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Table 5
Surrogate variables of organ function and injury
Baseline 12 hours 24 hours 36 hours 48 hours
Creatinine
(mg/dL)
TP 2.5 ± 1 2.6 ± 1.2 2.8 ± 1.4 2.8 ± 1.3 2.8 ± 1.4
AVP 2.2 ± 1 2.4 ± 1.1 2.4 ± 1.2 2.5 ± 1.4 2.4 ± 1.2
NE 2.2 ± 1.6 2.6 ± 1.7 2.7 ± 1.7* 2.9 ± 1.8* 3.3 ± 2*
Creatinine, rel.
(%)
TP -- 4 ± 16 11 ± 23 13 ± 27 14 ± 35§
AVP -- 11 ± 17 12 ± 26 15 ± 31 10 ± 21§
NE -- 19 ± 23 23 ± 37 34 ± 48 54 ± 77†‡
Bilirubin, tot.
(mg/dL)
TP 1.2 ± 0.7 1 ± 0.5 1 ± 0.5 0.9 ± 0.3‡§ 0.9 ± 0.3‡§
AVP 1.6 ± 1.3 1.6 ± 1.2 1.8 ± 1.6 2.0 ± 2.0† 2.3 ± 2.8†
NE 1.6 ± 0.9 1.9 ± 0.8 2.0 ± 1.2 2.3 ± 1.7*† 2.8 ± 2.5*†
Bilirubin, dir.
(mg/dL)
TP 0.5 ± 0.3 0.5 ± 0.4 0.5 ± 0.3 0.4 ± 0.2§ 0.3 ± 0.1‡§
AVP 0.8 ± 0.9 1 ± 1.2 1.1 ± 1.4 1.1 ± 1.5 1.4 ± 1.9*†
NE 0.8 ± 0.5 1.2 ± 0.8 1.2 ± 0.9 1.6 ± 1.7*† 1.9 ± 2.1*†
ASAT
(U/L)
TP 52 ± 26 52 ± 33 54 ± 35 53 ± 42 48 ± 34
AVP 63 ± 49 85 ± 57 79 ± 66 119 ± 163 91 ± 95
NE 72 ± 68 89 ± 115 95 ± 132 103 ± 146 90 ± 122
ALAT
(U/L)
TP 30 ± 14 34 ± 15 33 ± 14 35 ± 18 30 ± 13
AVP 45 ± 31 58 ± 42 63 ± 53 69 ± 67 81 ± 85
NE 43 ± 45 62 ± 80 68 ± 103 73 ± 114 63 ± 97
Amylase
(U/L)
TP 168 ± 97 148 ± 90 133 ± 79 127 ± 79 144 ± 124
AVP 165 ± 111 152 ± 100 143 ± 79 147 ± 110 123 ± 70
NE 203 ± 191 199 ± 182 217 ± 221 206 ± 212 172 ± 152
Lipase
(U/L)
TP 138 ± 145 125 ± 92 97 ± 64 144 ± 126 116 ± 91
AVP 133 ± 90 124 ± 68 127 ± 64 136 ± 72 134 ± 65
NE 134 ± 160 198 ± 282 120 ± 96 158 ± 162 115 ± 65
Troponine I
(ng/mL)
TP 0.31 ± 0.3 0.31 ± 0.51 0.22 ± 0.41 0.19 ± 0.35 0.18 ± 0.3Critical Care    Vol 13 No 4    Morelli et al.
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0.03·U/min. It might be argued that a weight-adjusted TP dose
was compared with a fixed AVP dose and thus the chosen
doses might not have been pharmacologically equivalent.
Therefore, it is possible that the TP dose was relatively higher
as compared with the AVP dose.
Second, we performed a pilot study with the reduction of
open-label NE requirements as the primary endpoint. In this
regard, it has to be underlined that there is no reliable evidence
that a reduction in catecholamine requirements may lead to an
improved outcome. Third, we investigated only a small number
of septic shock patients treated over a relative brief period. In
this regard, the risk of positive results in a study with numerous
secondary variables and time points has to be taken into
account. Thus, caution should be exercised in interpreting the
results of the secondary outcome variables. Properly powered,
randomized controlled trials are required to determine the
effects of TP infusion on clinical outcome. All patients included
in the present study received hydrocortisone, so we cannot
judge if and how corticosteroids affected our results [41,42].
For safety reasons, we opted for a 48-hour intervention period,
because it was impossible to measure the circulating levels of
TP. Although there is no evidence of drug accumulation over
time, we cannot rule out this possibility when TP is infused
over a more prolonged period. Moreover, hepatosplanchnic
perfusion was assessed using PDR and CBI. Although PDR
and CBI have been found to be a good predictor of survival in
critically ill patients, at best it reflects the total splanchnic
blood flow without separating hepatic arterial from portal
venous flow. In addition, mucosal blood flow was estimated by
gastric tonometry, a methodology that does not necessarily
reflect changes in other parts of the gastrointestinal tract.
Conclusions
Taken together, our results demonstrate that a continuous
infusion of a relatively low dose of TP (1.3 μg/kg/h) was effec-
tive in reversing sepsis-induced hypotension and in reducing
NE requirements. Larger randomized controlled clinical trials
are necessary to explicitly clarify whether or not low-dose TP
infusion may improve the overall outcome of patients with sep-
tic shock as compared with standard therapy. Awaiting these
results, continuous TP infusion should not be routinely used
outside the scope of controlled clinical trials and might be con-
sidered as a rescue therapy, when catecholamines are no
longer effective.
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AVP 0.56 ± 1 0.84 ± 1.5 1.23 ± 2.4 1.37 ± 2.5 1.17 ± 2
NE 0.58 ± 0.9 0.66 ± 0.8 0.72 ± 0.75 0.69 ± 0.86 0.63 ± 1
Platelet count
(103 cells/μL)
TP 119 ± 68 103 ± 59 93 ± 59* 78 ± 48* 73 ± 41*
AVP 110 ± 56 102 ± 63 95 ± 53 95 ± 55 93 ± 50
NE 114 ± 64 102 ± 52 99 ± 58 94 ± 60 94 ± 69
INR
TP 1.4 ± 0.2 1.4 ± 0.2 1.4 ± 0.2 1.4 ± 0.2 1.4 ± 0.2
AVP 1.5 ± 0.5 1.5 ± 0.3 1.5 ± 0.5 1.5 ± 0.4 1.5 ± 0.5
NE 1.5 ± 0.3 1.5 ± 0.3 1.4 ± 0.4 1.3 ± 0.2 1.4 ± 0.3
APTTr
TP 1.7 ± 0.6 1.6 ± 0.5 1.6 ± 0.4 1.8 ± 0.6 1.7 ± 0.7
AVP 1.5 ± 0.5 1.5 ± 0.6 1.6 ± 0.7 1.6 ± 0.7 1.7 ± 0.7
NE 1.5 ± 0.2 1.4 ± 0.2 1.4 ± 0.2 1.4 ± 0.2 1.6 ± 0.3
ALAT = alanine aminotransferase; aPTTr = activated partial thromboplastin time ratio; ASAT = aspartate aminotransferase; AVP = arginine 
vasopressin; Creatinine rel = relative increase in creatinine concentrations from baseline; INR = international normalized ratio; NE = 
norepinephrine; TP = terlipressin.
* P < 0.05 vs. baseline (significant time effect); † P < 0.05 vs. TP (significant group effect); ‡ P < 0.05 vs. AVP (significant group effect); § P < 0.05 
vs. NE (significant group effect).
Table 5 (Continued)
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